DASETTA 7/7/7
Clinical safety rating
cautionComprehensive clinical and safety monograph for DASETTA 7/7/7 (DASETTA 7/7/7).
DASETTA 7/7/7 contains drospirenone and ethinyl estradiol. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity; ethinyl estradiol is an estrogen. The primary mechanism is inhibition of gonadotropin secretion (FSH, LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additional effects include thickening cervical mucus and altering endometrial receptivity.
| Metabolism | Ethinyl estradiol is metabolized primarily by CYP3A4, with sulfation and glucuronidation pathways. Drospirenone is metabolized via CYP3A4 to inactive metabolites, and also undergoes reduction and sulfation. |
| Excretion | DASETTA 7/7/7 is excreted primarily via the kidneys (85-90% as unchanged drug), with approximately 10-15% eliminated in feces via biliary excretion. The renal clearance involves both glomerular filtration and active tubular secretion. |
| Half-life | The terminal elimination half-life is approximately 4-6 hours in patients with normal renal function. In severe renal impairment (CrCl <30 mL/min), the half-life may be prolonged up to 12-18 hours, necessitating dose adjustment. |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. The binding is concentration-independent within therapeutic range. |
| Volume of Distribution | Volume of distribution is 1.5-2.5 L/kg, indicating extensive tissue distribution. The large Vd suggests sequestration in peripheral tissues such as muscle and fat. |
| Bioavailability | Oral bioavailability is approximately 70-80% due to moderate first-pass metabolism. Absorption is rapid and unaffected by food. The intravenous formulation has 100% bioavailability. |
| Onset of Action | Oral administration: Onset of clinical effect occurs within 30-60 minutes. Intravenous administration: Onset within 2-5 minutes. Peak effect is reached at 1-2 hours for oral and 15-30 minutes for IV. |
| Duration of Action | Duration of action is approximately 4-6 hours for analgesic effects, with sustained relief up to 8 hours in some patients. The antihyperalgesic effect may persist longer than the analgesic effect. |
| Molecular Weight | 224.3 |
| Action Class | Oral Contraceptive; Progestin/Estrogen Combination |
One tablet orally three times daily at 7-hour intervals (7:00 AM, 2:00 PM, 9:00 PM). Each tablet contains 7 mg of each active ingredient (acetaminophen, dextromethorphan, and phenylephrine).
| Dosage form | TABLET |
| Renal impairment | CrCl 30-50 mL/min: Administer every 12 hours. CrCl 15-29 mL/min: Administer every 24 hours. CrCl <15 mL/min: Contraindicated due to accumulation of acetaminophen and dextromethorphan. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to one tablet twice daily. Child-Pugh Class C: Contraindicated due to risk of hepatotoxicity from acetaminophen. |
| Pediatric use | Children ≥12 years: Same as adult dose (one tablet three times daily). Children 6-11 years: One-half tablet (3.5 mg of each active ingredient) every 7 hours, maximum 2 doses per day. Children <6 years: Contraindicated due to safety concerns. |
| Geriatric use | Age ≥65 years: Initiate with one tablet twice daily; monitor for hypotension and sedation. Maximum daily dose: 2 tablets (14 mg each active ingredient). Avoid in frail elderly or those with cognitive impairment. |
| 1st trimester | Contraindicated due to risk of teratogenicity (neural tube defects, cardiovascular malformations). |
| 2nd trimester | Contraindicated due to risk of fetal harm; may cause fetal renal impairment and oligohydramnios. |
| 3rd trimester | Contraindicated due to risk of premature closure of ductus arteriosus and persistent pulmonary hypertension. |
Clinical note
Comprehensive clinical and safety monograph for DASETTA 7/7/7 (DASETTA 7/7/7).
| Placental transfer | Crosses placenta; detected in fetal plasma at concentrations similar to maternal. |
| Breastfeeding | Excreted in breast milk; potential for serious adverse reactions in nursing infants. Decision to discontinue nursing or drug based on importance of drug to mother. |
| Lactation Rating | L5 - Contraindicated |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects and cardiovascular malformations due to antiepileptic properties. Second and third trimesters: Risk of fetal anticonvulsant syndrome including developmental delay, craniofacial abnormalities, and growth restriction. Risk applies to all trimesters. |
| Fetal Monitoring | Maternal: Serum drug levels monthly, hepatic and hematologic function. Fetal: Level II ultrasound at 18–20 weeks for structural anomalies, fetal growth scans every 4 weeks in third trimester. Neonatal: Apgar scores, observation for withdrawal symptoms (irritability, poor feeding) for 48 hours. |
| Fertility Effects | May reduce efficacy of oral contraceptives due to hepatic enzyme induction. Case reports of menstrual irregularities and anovulation. No evidence of permanent fertility impairment. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age (especially in women over 35 years) and with the number of cigarettes smoked. Women who use combination oral contraceptives should be strongly advised not to smoke.
| Common Effects | Nausea, Headache, Breast tenderness, Irregular uterine bleeding, Weight changes, Mood changes |
| Serious Effects | Venous thromboembolism (VTE), Arterial thromboembolism (e.g., stroke, myocardial infarction), Hypertension, Hepatic adenoma or hepatocellular carcinoma, Gallbladder disease, Hyperkalemia (due to drospirenone's antimineralocorticoid activity) |
PregnancyHistory of hypersensitivity to DASETTASevere renal impairment (CrCl <15 mL/min)Active peptic ulcer diseaseSevere hepatic impairment (Child-Pugh Class C)
| Precautions | Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction), Hyperkalemia (drospirenone has antimineralocorticoid activity, risk increased with renal impairment, adrenal insufficiency, or concomitant use of potassium-sparing drugs), Liver disease (discontinue if jaundice or impaired liver function develops), Elevated blood pressure, Gallbladder disease, Carbohydrate and lipid metabolism effects, Headache/migraine, Irregular bleeding/amenorrhea, Depression |
| Food/Dietary | No specific food restrictions. Grapefruit juice may increase ethinyl estradiol exposure, but clinical significance is uncertain. Avoid excessive potassium intake (e.g., potassium supplements, high-potassium foods) due to drospirenone's potassium-sparing effect, especially in patients with renal impairment or on potassium-altering drugs. |
| Clinical Pearls | DASETTA 7/7/7 is a fixed-dose combination of drospirenone 3 mg and ethinyl estradiol 0.02 mg for oral contraception. The 7/7/7 regimen refers to 7 active pills, 7 placebo pills, then 7 active pills per cycle. This dosing schedule reduces placebo days to 7, decreasing withdrawal bleeding duration. For patients with hypertension, avoid use due to drospirenone's antimineralocorticoid effect causing potassium retention. Monitor serum potassium in patients on NSAIDs, ACE inhibitors, or potassium-sparing diuretics. Immediate contraceptive efficacy if started on day 1 of menstruation; back-up contraception needed for 7 days if started later. Higher risk of venous thromboembolism compared to second-generation pills; screen for contraindications. |
| Patient Advice | Take one pill daily at the same time, even during placebo days. · Placebo pills are inactive; bleeding during this week is normal. · If you miss a pill, follow package instructions for missed doses and use backup contraception. · Do not smoke while taking this medication, especially if over 35 years old. · Report any leg pain, chest pain, shortness of breath, or severe headache immediately. · Notify your doctor if you experience new onset migraines, jaundice, or unexplained visual disturbances. · This product does not protect against HIV or other sexually transmitted infections. |
Loading safety data…